Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
NCT06745882
This study is recruiting at 11 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Last updated on ClinicalTrials.gov
- September 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Louisiana · 1
- Our Lady of the Lake Physician's Group · Baton Rouge, LA
Maryland · 5
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, MD
- Medstar Franklin Square · Baltimore, MD
- Sinai Hospital of Baltimore · Baltimore, MD
- University of Maryland Greenebaum Cancer Center · Baltimore, MD
- TidalHealth Peninsula Regional · Salisbury, MD
New York · 1
- Montefiore Medical Cancer Center · The Bronx, NY
North Carolina · 1
- FirstHealth of the Carolinas, Inc. · Pinehurst, NC
Tennessee · 2
- Baptist Clinical Research Institute · Memphis, TN
- Nashville General Hospital · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.